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Abstract 
Purpose: To modify the structure of oxyresveratrol and evaluate the obtained derivatives for effects on 
neuronal cells. 
Methods: Electron-withdrawing groups were selectively introduced to the aromatic ring of the core 
stilbene structure. Oxyresveratrol and derivatives were then evaluated for their ability to enhance the 
survival of P19 derived neuronal cells by XTT method, in comparison with the widely known 
antioxidants, Trolox and ascorbic acid. Phase-contrast microscopic images of the neurons under 
various conditions were also taken and analyzed. 
Results: Oxyresveratrol, at a very low concentration (1 ng/mL), enhanced the survival of neurons in 
both normal and serum-deprivation conditions. Higher activity was observed for the 5-formylated and t 
5-carboxylated products. The potencies of these polyoxygenated stilbenes were far greater than those 
of Trolox and ascorbic acid. These observations were supported by results from the examination of the 
phase-contrast micrographs of the neuronal cells. 
Conclusion: Oxyresveratrol and some derivatives prepared in this study demonstrate significant cell 
protective activity and may be of therapeutic value, but further investigations in animals are required to 
verify their neuroprotective potentials. 
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As the world’s ageing population continues to 
grow at an unprecedented rate, the number of 
people affected by neurodegenerative disorders, 
such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) is rising rapidly [1-3]. 
Although the etiology of these ageing-related 
diseases is still unclear, oxidative stress has 
been implicated in their pathogenesis [4,5]. 
 
Oxyresveratrol (2,4,3`,5`-tetrahydroxystilbene, 1) 
is a phytoalexin found in large quantities in 
several members of the family Moraceae, for 
example, Artocarpus lacucha Buch.-Ham. 
(formerly known as A. lakoocha Roxb.) and 
Morus alba L. [6,7]. Our previous studies have 
shown that 1 possesses a wide range of 
biological activities, for example, anti-herpetic 
activity, inhibitory effect on tyrosinase and 
protective activity against DNA damage [8-10]. In 
recent years, considerable amounts of research 
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have been published on the possible 
neuroprotective effects of 1. Studies have shown 
that 1 could protect cultured neurons from β-
amyloid-induced toxicity and defend 
neuroblastoma cells against 6-hydroxydopamine, 
suggesting potential applications for AD and PD, 
respectively [11,12]. The compound was also 
studied for protective effects against cerebral 
ischemia in vivo [13], and traumatic injury in vitro 
[14]. Its antioxidant activity has been investigated 
in several models [7,15,16]. 
 
P19 embryonal carcinoma cells have been 
shown to differentiate into neurons when cultured 
in the presence of all trans retinoic acid and 
cytosine arabinoside (Ara-C), and they have 
been recently employed as a tool in neurological 
research [17].  
 
In this communication, we wish to report the 
effects of oxyresveratrol (1) and some derivatives 
(2 – 4) on the cell viability of P19-derived 






Melting points (uncorrected) were measured on a 
Fisher-Johns hot stage melting point apparatus. 
IR spectra were recorded using UATR (Universal 
Attenuated Total Reflectance) on a Perkin Elmer 
system 2000 FT-IR or Jasco A-30 
Spectrophotometer. High resolution mass 
spectra were taken on a MicroTOF instrument 
(APCI or ESI) in positive or negative mode. 1H 
and 13C-NMR were recorded on a Bruker Avance 
III 300 MHz spectrometer or Bruker 400 
spectrometer. All chemical shift values were 
reported as  (ppm) with the solvent signal as 
reference, and coupling constant values J were 
measured in Hz. 
 
Plant material and isolation of oxyresveratrol 
(1) 
 
The collection and botanical identification of the 
heartwood of Artocarpus lacucha Buch.-Ham. (A. 
lakoocha Roxb.), and the isolation and chemical 
identification of 1 were carried out as previously 
described [18]. 
 
Synthesis of compounds 2 - 4 
 
Compounds 2 – 4 were prepared through the 
intermediates 1a – 1f, following the previously 
reported synthetic routes [16]. 
 
Synthesis of 3′,5′-dihydroxy-2,4-diisopropo-
xystilbene (1a) and 2,3′,4,5′-tetraisopropoxy-
stilbene (1b) 
 
K2CO3 (5.67 g, 41 mmol) and 2-bromopropane 
(6.2 mL, 66.3 mmol) were added to a solution of 
DMF (20 mL) containing compound 1 (2 g, 8.20 
mmol). Then 2-bromopropane (3.1 mL, 33.1 
mmol) was added every 24 h. The reaction 
mixture was stirred at 55 °C for 3 days and 
monitored by TLC. After completion, water (20 
mL) was added and the reaction was extracted 
with EtOAc (3 x 20 mL). The organic phase was 
washed with water (7 x 20 mL) and brine, dried 
over Na2SO4, filtered and concentrated. Column 
chromatographic purification with gradient 
EtOAc/hexane gave 1a (0.52 g, 19 %) and 1b 





To the solution of CH2Cl2 (8 mL) containing 
compound 1a (212 mg, 0.65 mmol), Et3N (0.2 
mL, 1.44 mmol) and acetic anhydride (0.13 mL, 
1.37 mmol) were added and stirred for 2 h at 
room temperature. Then the reaction mixture 
was diluted with water (10 mL) and extracted 
with EtOAc (3 x 10 mL). The organic phase was 
washed with brine, dried with Na2SO4 and 
concentrated in vacuo to give a crude product. 
Purification with column chromatography eluting 






POCl3 (0.61 mL, 6.64 mmol) was stirred with dry 
DMF (5 mL) at room temperature for 2 h under 
argon. The solution of 1c (273 mg, 0.66 mmol) in 
dry DMF (5 mL) was added at 0 °C. Then the 
reaction mixture was allowed to warm to room 
temperature and stirred overnight. After 
completion of the reaction, cool water (10 mL) 
was added and the reaction mixture was 
extracted with EtOAc (3 x 10 mL). The organic 
layer was washed with water (7 x 10 mL) and 
brine, dried with Na2SO4 and concentrated in 
vacuo to give a crude product, which was purified 
by preparative TLC (20 % EtOAc/hexanes) to 





A solution of water (0.5 mL) containing NaClO2 
(135 mg, 1.49 mmol) and NaH2PO4·2H2O (237 
mg, 1.52 mmol) was added to a solution of 
acetone (0.5 mL) containing compound 1d (82 
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mg, 0.19 mmol) and 2-methyl-2-butene (0.06 mL, 
0.71 mmol) and stirred for 1h at room 
temperature. After completion, the reaction 
mixture was diluted with water (5 mL) and 
extracted with EtOAc (3 x 5 mL). The organic 
layer was washed with brine, dried with Na2SO4 
and concentrated in vacuo to give a crude 
product, which was purified by column 
chromatography on silica (40 % EtOAc/hexanes) 





POCl3 (0.31 mL, 3.38 mmol) was stirred with dry 
DMF (8 mL) at room temperature for 2 h under 
argon. A solution of 1b (400 mg, 0.97 mmol) in 
dry DMF (8 mL) was added at 0 °C and the 
reaction mixture was further stirred overnight. 
After completion of the reaction, cool water (15 
mL) was added and extracted with EtOAc (3 x 15 
mL). The organic layer was washed with water (7 
x 15 mL) and brine, dried over Na2SO4, filtered 
and followed by removal of the solvent under 
reduced pressure to give a crude product, which 
was purified by column chromatography on silica 






A solution of BCl3 (1.69 mL, 1.69 mmol) was 
added to a solution of 1d (121 mg, 0.27 mmol) in 
CH2Cl2 (4 mL) at 78 °C under argon. Then it 
was allowed to warm to room temperature and 
stirred overnight. Water (5 mL) was then added 
and the reaction mixture was extracted with 
EtOAc (3 x 5mL). The EtOAc was washed with 
brine, dried with Na2SO4 and concentrated in 
vacuo to give a crude product which was purified 
by preparative TLC (40 % EtOAc/hexanes) to 





A solution of BCl3 (0.85 mL, 0.85 mmol) was 
added to a solution of 1e (65 mg, 0.14 mmol) in 
CH2Cl2 (2 mL) at 78 °C under argon. Then the 
reaction was allowed to warm to room 
temperature and stirred overnight. Water (5 mL) 
was added and the mixture was extracted with 
EtOAc (3 x 5 mL).  
 
The organic layer was washed with brine, dried 
with Na2SO4 and concentrated in vacuo to give a 
crude product which was purified by Sephadex 





Compound 1f (292 mg, 0.66 mmol) was 
dissolved in 10 mL of CH2Cl2. To this solution, 
BCl3 (5.32 mL, 5.32 mmol) was added at -78 °C 
under argon. The reaction was allowed to warm 
up to room temperature and stirred overnight. 
Then, water (10 mL) was added, and the reaction 
was extracted with EtOAc (3 x 10 mL). The 
EtOAc phase was washed with brine, dried with 
Na2SO4 and concentrated in vacuo to give a 
crude product which was purified by using 
preparative TLC (40 % EtOAc/hexanes) to give 4 
(100 mg, 56 %). 
 
Evaluation of superoxide free radical anion 
scavenging activity 
 
The compounds were determined according to 
established protocols. The assay was based on 
the capacity of the test sample to inhibit the 
reduction of nitroblue tetrazolium (NBT) in the 
riboflavin-light-NBT system. A 96-well microplate 
was used. The reaction mixture (200 μL) in each 
well contained 20 μL of 50 mM potassium 
phosphate buffer,100 μL of 266 μM riboflavin, 20 
μL of 1 mM EDTA, 20μL of 750 μM NBT and 40 
μL of sample solution. The production of blue 
formazan was monitored by measuring the 
increase in absorbance at 570 nm after a 10-min 
illumination with a fluorescent lamp. The entire 
reaction proceeded in a closed box lined with 
aluminum foil. A similar reaction mixture was 
kept in the dark and served as the blank. 
 
Assays for effects on P19-derived neurons 
 
Compounds were evaluated for their effects on 
P19-derived neurons following previously 




Murine embryonal carcinoma cells, P19 ATCC 
CRL-1857, obtained from the American Type 
Culture Collection, USA, were grown in alpha 
minimal essential medium (-MEM) with 7.5 % 
new born calf serum (NCS), 2.5 % fetal bovine 
serum (FBS), and 1 % antibiotics-antimycotic 
solution (P19GM) in a 5 % CO2 humidified 
atmosphere, at 37 C. Cells in monolayer 
cultures were maintained in exponential growth 
by subculturing every 2 days. 
 
Differentiation of P19 cells into neurons 
 
The exponentially grown cultures indicated the 
cells density by trypan blue exclusion assay. 
Then, neuronal differentiation was induced by 
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seeding 2  106 cells/mL cell in a 100 mm 
bacteriological grade culture dish containing 10 
mL -MEM supplemented with 5 % FBS, 1 % 
antibiotic-antimycotic solution, and 0.5 μM all 
trans-retinoic acid (RA). Under these conditions, 
cells did not adhere to dishes but instead formed 
large aggregates in suspension (neurospheres). 
After 4 days of RA treatment, aggregates were 
dissociated with glass pipette, washed, and then 
resuspended on poly-L-lysine-precoated 96-well 
plates (plates previously coated with 50 μg/mL 
poly-L-lysine in PBS for overnight and sterilized 
under UV light for 30 min) at a cell density of 7  
104 cells/mL (150 μL/well) in -MEM 
supplemented with 10 % FBS and 1 % 
antibiotics-antimycotic solution, and incubated for 
24 h. Ara-C (10 μM) was added at day one after 
plating to inhibit the proliferation of nonneuronal 
cells. The medium was changed every 2 - 3 
days. The differentiated P19-derived neurons 
were used after day 14 of the differentiation 
process. 
 
Assay for cell viability under normal 
condition 
 
The assay was performed in triplicate. After 14 
days of differentiation process, the medium (-
MEM supplemented with 10 % FBS, 10 μM Ara-
C and 1 % antibiotics-antimycotic solution) was 
removed, and replaced with a DMSO solution of 
test compound in P19SM (-MEM supplemented 
with 10 % FBS). Thereafter, a 1 % antibiotic-
antimycotic solution containing 10 μM Ara-C was 
added to give a final concentration of the test 
sample at 1, 10 or 100 ng/mL. The final DMSO 
content in each well was kept at 0.5 %, which 
had no effect on the cells. The blank control wells 
were filled with the corresponding medium 
(P19SM, 10 μM Ara-C, and 1 % antibiotics-
antimycotic solution). The cells were incubated 
for 18 h at 37 C. Then, the medium was 
removed, and 50 L of XTT solution (1 mg/mL 
XTT in -MEM and 25 M 
phenazinemethosulfate) was added. After 
incubation at 37 C for 4 h, 100 L of PBS was 
added. The OD value was determined on a 
microplate reader at 450 nm. The data were 
expressed as the mean ± SEM (n = 3), with the 
medium as a control representing 100 % cell 
viability. The concentration that enhanced the 
survival of cultured neurons more than control 
will be further investigated for neuroprotective 
activity. 
 
Assay for cell viability under serum-
deprivation condition 
 
The assays were carried out in a 96-well plate 
and performed in triplicate. For serum deprivation 
condition, the cells were fed with medium without 
FBS (-MEM supplemented with 10 M Ara-C, 
and 1 % antibiotic-antimycotic solution), and a 
DMSO solution of test compound was added. 
DMSO (0.5 %) was used as the control. The cells 
were incubated for 18 h at 37 C. Cell viability 
was assayed by the XTT reduction method. 
 
Statistical analysis  
 
A mean viability of the cells was statistically 
analyzed by Student’s t-test to compare the 
statistical significance between either the control 
or oxidative stress conditions and experimental 
groups. Differences were considered significant 






Compounds 2-4 were prepared from 1 following 
earlier reported protocols with slight modification 
[16], as shown in Figure 1. The synthetic route 
began with the reaction of oxyresveratrol (1) with 
2-bromopropane to give di- and tetra-O-isopropyl 
products (1a and 1b). Compound 1a was then O-
acetylated on ring B to give 1c. This intermediate 
(1c) was formylated at C-5 by Vilsmeier-Haack 
reaction to give 1d which, after deprotection with 
BCl3, furnished compound 2. Oxidation of 1d by 
NaClO2 gave the corresponding 1e which was 
subsequently converted into 3, after BCl3-
mediated cleavage of all the O-protecting groups. 
Finally, compound 4 was obtained from the 
Lewis-catalyzed hydrolysis reaction of 1f, which 
was earlier prepared from 1b through the 
Vilsmeier-Haack formylation at C-2`. 
 
1a: 3′,5′-Dihydroxy-2,4-diisopropoxystilbene: 
brown oil; IR (UATR, cm−1): 3379, 2976, 1598; 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.43 (d, J = 
8.4 Hz, 1H), 7.31 (d, J = 16.4 Hz, 1H), 6.84 (d, J 
= 16.4 Hz, 1H), 6.56 (d, J = 2.1 Hz, 2H), 6.48 
(dd, J = 8.5, 2.3 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 
6.25 (br s, 1H), 4.52 (m, 2H), 1.35 (d, J = 6 Hz, 
6H), 1.33 (d, J = 6 Hz, 6H); 13C-NMR (100 MHz, 
CDCl3), δ (ppm): 158.6, 157.0, 156.5, 141.0, 
127.4, 126.1, 124.3, 120.3, 107.5, 105.8, 103.2, 
101.7, 71.2, 70.1, 22.1, 22.0; TOF-HRMS m/z [M 
− H]−, calcd for C20H23O4: 327.1602; found: 
327.1594. These physical and spectroscopic 
properties are in agreement with earlier reported 
values [16]. 
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R 1  =  iP r
R 2  =  A c
   
Figure 1: Reagents and conditions: (a) 2-bromopropane, K2CO3, DMF, 55 °C; (b) Ac2O, Et3N, CH2Cl2, rt; (c) 
POCl3, DMF, 0 °C, Ar; (d) ; BCl3, CH2Cl2, 78 °C rt, Ar; (e) NaClO2, NaH2PO42H2O, 2-methyl-2-butene, 
acetone, rt 
 
1b: 2,3′,4,5′-Tetraisopropoxystilbene: white solid, 
mp 58–60 °C; IR (UATR, cm−1): 2976, 1585; 1H-
NMR (300 MHz, CDCl3), δ (ppm): 7.46 (d, J = 8.4 
Hz, 1H), 7.33 (d, J = 16.4 Hz, 1H), 6.91 (d, J = 
16.4 Hz, 1H), 6.62 (d, J = 2.2 Hz, 2H), 6.49 (dd, J 
= 8.5, 2.3 Hz, 1H), 6.45 (d, J = 3.9 Hz, 1H), 6.34 
(t, J = 2.1 Hz, 1H), 4.55 (m, 4H), 1.37 (d, J = 6 
Hz, 6H), 1.35 (d, J = 6 Hz, 12H), 1.34 (d, J = 6 
Hz, 6H); 13C-NMR (75 MHz, CDCl3), δ (ppm): 
159.1, 158.6, 156.6, 140.5, 127.4, 126.7, 124.2, 
120.4, 107.3, 106.4, 103.0, 102.5, 71.0, 69.9, 
69.8, 22.2, 22.1; TOF-HRMS m/z [M + H]+, calcd 
for C26H37O4: 413.2686; found: 413.2679. These 
physical and spectroscopic properties are in 
agreement with earlier reported values [16]. 
 
1c: 3′,5′-Diacetoxy-2,4-diisopropoxystilbene: 
white solid, mp 65–67 °C; IR (UATR, cm−1): 
2978, 1768, 1599; 1H-NMR (300 MHz, CDCl3), δ 
(ppm): 7.41 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 16.5 
Hz, 1H), 7.08 (d, J = 2.1 Hz, 2H), 6.94 (d, J = 
16.2 Hz, 1H), 6.78 (t, J = 2.1 Hz, 1H), 6.46 (dd, J 
= 8.1, 2.4 Hz, 1H), 6.45 (br s, 1H), 4.51 (m, 2H), 
2.25 (s, 6H), 1.36 (d, J = 6 Hz, 6H), 1.31 (d, J = 6 
Hz, 6H); 13C-NMR (75 MHz, CDCl3), δ (ppm): 
168.7, 158.8, 156.6, 151.0, 140.7, 127.6, 125.8, 
124.6, 119.4, 116.3, 113.3, 106.9, 102.5, 70.6, 
69.7, 21.9, 21.8, 20.8; TOF-HRMS m/z [M + 
Na]+, calcd for C24H28NaO6: 435.1778; found: 
435.1796. These physical and spectroscopic 




bene: viscous yellow oil; IR (UATR, cm−1): 2979, 
1768, 1671, 1593; 1H-NMR (300 MHz, CDCl3), δ 
(ppm): 10.32 (s, 1H), 8.03 (s, 1H), 7.27 (d, J = 
16.5 Hz, 1H), 7.08 (d, J = 1.8 Hz, 2H), 7.03 (d, J 
= 16.5 Hz, 1H), 6.81 (t, J = 2.1 Hz, 1H), 6.44 (s, 
1H), 4.66 (m, 2H), 2.29 (s, 6H), 1.43 (d, J = 6 Hz, 
6H), 1.40 (d, J = 6 Hz, 6H); 13C-NMR (75 MHz, 
CDCl3), δ (ppm): 188.1, 168.7, 161.8, 161.4, 
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151.0, 140.1, 126.6, 126.3, 124.2, 119.6, 118.8, 
116.4, 113.8, 98.1, 71.2, 70.9, 21.67, 21.66, 
20.8; TOF-HRMS m/z [M + Na]+, calcd for 
C25H28NaO7: 463.1727; found: 463.1743. These 
physical and spectroscopic properties are in 
agreement with earlier reported values [16]. 
 
1e: 3′,5′-Diacetoxy-5-carboxy-2,4-diisopropoxy-
stilbene: white solid, mp 106–108 °C; IR (UATR, 
cm−1): 3267, 2980, 1769, 1732, 1601; 1H-NMR 
(300 MHz, CDCl3), δ (ppm): 8.35 (s, 1H), 7.26 (d, 
J = 16.5 Hz, 1H), 7.09 (d, J = 2.1 Hz, 2H), 7.08 
(d, J = 16.5 Hz, 1H), 6.82 (t, J = 2.1 Hz, 1H), 6.50 
(s, 1H), 4.83 (sept, J = 6 Hz, 1H), 4.65 (sept, J = 
6 Hz, 1H), 2.31 (s, 6H), 1.51 (d, J = 6 Hz, 6H), 
1.45 (d, J = 6 Hz, 6H); 13C-NMR (75 MHz, 
CDCl3), δ (ppm): 168.9, 165.3, 160.2, 157.2, 
151.2, 140.1, 132.1, 127.5, 123.9, 121.4, 116.8, 
114.2, 110.9, 99.0, 74.2, 71.4, 21.92, 21.88, 
21.0; TOF-HRMS m/z [M + Na]+, calcd for 
C25H28NaO8: 479.1676; found: 479.1695. These 
physical and spectroscopic properties are in 
agreement with earlier reported values [16]. 
 
1f: 2′-Formyl-2,3′,4,5′-tetraisopropoxystilbene: 
viscous yellow oil; IR (UATR, cm−1): 2976, 1671, 
1586; 1H-NMR (300 MHz, CDCl3), δ (ppm): 10.53 
(s, 1H), 8.08 (d, J = 16.4 Hz, 1H), 7.60 (d, J = 8.6 
Hz, 1H), 7.30 (d, J = 16.4 Hz, 1H), 6.75 (d, J = 
2.1 Hz, 1H), 6.50 (dd, J = 8.6, 2.3 Hz, 1H), 6.44 
(d, J = 2.4 Hz, 1H), 6.35 (d, J = 2.1 Hz, 1H), 4.69 
(sept, J = 6 Hz, 1H), 4.48–4.63 (m, 3H), 1.33–
1.41 (m, 24H); 13C-NMR (75 MHz, CDCl3), δ 
(ppm): 191.1, 163.6, 162.7, 158.9, 156.7, 143.9, 
128.1, 127.3, 125.4, 120.4, 116.8, 107.4, 105.0, 
102.9, 100.1, 71.4, 70.9, 70.1, 69.9, 22.2, 22.04, 
21.98; TOF-HRMS m/z [M + H]+, calcd for 
C27H37O5: 441.2635; found: 441.2639. These 
physical and spectroscopic properties are in 
agreement with earlier reported values [16]. 
 
2: 5-Formyl-2,3′,4,5′-tetrahydroxystilbene: yellow 
solid, decomposed >205 °C; IR (UATR, cm−1): 
3208, 1626; 1H-NMR (300 MHz, methanol-d4), δ 
(ppm): 9.69 (s, 1H), 7.76 (s, 1H), 7.27 (d, J = 
16.5 Hz, 1H), 6.95 (d, J = 16.5 Hz, 1H), 6.47 (d, J 
= 2.4 Hz, 2H), 6.25 (s, 1H), 6.16 (t, J = 2.1 Hz, 
1H); 13C-NMR (75 MHz, methanol-d4), δ (ppm): 
194.9, 167.8, 164.8, 159.6, 141.6, 133.2, 128.4, 
123.8, 121.0, 115.5, 105.9, 103.7, 102.7; TOF-
HRMS m/z [M − H]−, calcd for C15H11O5: 
271.0612; found: 271.0603. These physical and 
spectroscopic properties are in agreement with 
earlier reported values [16]. 
 
3: 5-Carboxy-2,3′,4,5′-tetrahydroxystilbene: 
yellow solid, decomposed >230 °C; IR (UATR, 
cm−1): 3337, 1616; 1H-NMR (300 MHz, methanol-
d4), δ (ppm): 8.01 (s, 1H), 7.24 (d, J = 16.5 Hz, 
1H), 6.92 (d, J = 16.5 Hz, 1H), 6.49 (d, J = 2.1 
Hz, 2H), 6.36 (s, 1H), 6.19 (t, J = 2.1 Hz, 1H); 
13C-NMR (75 MHz, methanol-d4), δ (ppm): 173.5, 
164.2, 162.8, 159.6, 141.6, 130.0, 128.5, 123.8, 
118.9, 106.3, 105.8, 103.3, 102.7; TOF-HRMS 
m/z [M − H]−, calcd for C15H11O6: 287.0561; 
found: 287.0549. These physical and 
spectroscopic properties are in agreement with 
earlier reported values [16]. 
 
4: 2′-Formyl-2,3′,4,5′-tetrahydroxystilbene: yellow 
solid, decomposed >218 °C; IR (UATR, cm−1): 
3337, 1602; 1H-NMR (300 MHz, methanol-d4), δ 
(ppm): 10.17 (s, 1H), 7.55 (d, J = 15.9 Hz, 1H), 
7.38 (d, J = 9 Hz, 1H), 7.23 (d, J = 15.9 Hz, 1H), 
6.56 (d, J = 2 Hz, 1H), 6.33 (dd, J = 8.6, 2.3 Hz, 
1H), 6.32 (br s, 1H), 6.14 (d, J = 2 Hz, 1H); 13C-
NMR (75 MHz, methanol-d4), δ (ppm): 194.3, 
167.3, 167.2, 160.1, 158.0, 148.0, 131.8, 129.6, 
120.4, 117.2, 112.8, 108.5, 107.4, 103.6, 102.0; 
TOF-HRMS m/z [M − H]−, calcd for C15H11O5: 
271.0612; found: 271.0607. These physical and 
spectroscopic properties are in agreement with 




The effect of compounds 1 – 4 on superoxide 
radical scavenging activity and cell viability of 
P19-derived neuronal cells in normal condition 
are shown in Table 1 while the effect of stilbenes 
1 – 3 on the survival of the neurons cultured 
under serum-deprivation condition are displayed 
in Table 2 and Figure 2. Phase-contrast 
micrographs of neurons in the corresponding 
experiments are illustrated in Figure 3. 
 
It is clear from Figure 2 that pretreatment of the 
neurons with 1 ng/mL oxyresveratrol (1) could 
significantly reduce cell death, bringing the cell 
survival back to the level of 67.6%. It should be 
noted that compound 2 displayed statistically 
higher activity than 1 (p  0.05). On the contrary, 
the widely used antioxidants Trolox and ascorbic 
acid showed much lower activity than 1, 2 or 3, 
as reflected from their much greater amounts (15 
and 10 g/mL, respectively) required for the 
activity and the less percentages of cell survival 
(65.4 and 69.3 %, respectively). To further 
confirm the biological effects of these 
compounds (1 – 3), phase-contrast images of the 
neurons under various conditions were taken, 
and the results are illustrated in Figure 3. Figure 
3 (a and b) show the neuronal cells growing in 
normal and serum-starvation condition, 
respectively. It can be seen from Figure 3 (b) that 
nutrient starvation caused cell death and reduced 
neurite growth. These adverse effects were 
prevented by adding antioxidant ascorbic acid 
(10 g/mL) or Trolox (15 g/mL) to the medium, 
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Superoxide scavenging  
activity a Cell viability (%) 
b 
Inhibition 
at 100 g/mL IC50 (M)  1 ng/mL 10 ng/mL 100 ng/mL 
1 76.1  3.4 303.1  7.9  115.3 ± 10.5 99.8 ± 4.5 83.6 ± 19.8 
2 94.2   3.5 88.3  9.7  107.4 ± 4.7 - - 
3 96.0  3.6 38.6  1.4  109.0 ± 2.1 - - 
4 91.0  6.4 43.4  4.4  83.6 ± 3.1 - - 
Trolox 61.4  3.6 293.519.3  - - - 
aData from a previous report [16]; bcompared with untreated control 
 
    Table 2: Cell protective activity of compounds 1 – 3 
 
Compound Mean cell viability (± SEM, %) 
1 (1 ng/mL) 67.6  ± 0.9* 
2 (1 ng/mL) 75.2  ± 2.0* 
3 (1 ng/mL) 72.9  ± 2.0* 
Trolox (15 μg/mL) 65.4  ± 5.3* 
Ascorbic acid (10 μg/mL) 69.3 ± 3.8* 
α-MEM + 10 μM Ara-C + 0.5%DMSO (control of serum-deprivation condition) 40.9 ± 3.6 
α-MEM + 10 μM Ara-C (serum deprivation condition) 40.2  ± 6.8 
P19SM+ 10 μM Ara-C +0.5%DMSO (control of untreated control) 100.1 ± 1.9 
P19SM + 10 μM Ara-C (untreated control) 100.00 ± 0.00 
* P < 0.05 when compared with serum-deprivation condition and control of serum-deprivation condition;   P19SM 
consists of α-MEM+ 10 %v/v FBS; all culture media contain 1%v/v antibiotic-antimycotic solution 
 
 
Figure 2: Effect of compounds 1, 2 and 3 on cell viability of P19-derived neurons under oxidative stress induced 
by serum deprivation 
 
as depicted in Figure 3 (c and d). Interestingly, at 
a very much lower concentration (1 ng/mL), 
stilbenes 1, 2 and 3, each, enhanced cell 
survival, as well as helped to maintain neurite 




The reactivity of the two aromatic rings (A and B) 
of 1 toward electrophilic substitution was 
manipulated by employing different O-protecting 
groups (1b and 1c). In 1b, ring B was more 
sensitive to electrophilic attack than ring A, 
particularly at C-2 and C-6 positions, due to the 
electron donating effects from all of the four O-
isopropyl ether functionalities. However, in 1c, 
the B ring was deactivated by the two O-acetyl 
ester groups, and as a result, ring A was more 
receptive to electrophiles, specifically at C-5.
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Figure 3: Protective activity of 1, 2, and 3 on P19-derived neurons. Phase-contrast images of the neurons 
incubated for 18 h and treated with: (a) α-MEM with serum (untreated control); (b) α-MEM without serum; (c) 10 
μg/mL of ascorbic acid (positive control); (d) 15 μg/mL of Trolox (positive control); (e) 1 ng/mL of 1; (f) 1 ng/mL of 
2; and (g) 1 ng/mlL of 3; bar = 10 m at 100 
 
This difference in reactivity allowed for selective 
formylation on the two aromatic rings, and thus 
enabled the separate preparation of 5-
formyloxyresveratrol (2) and 2-
formyloxyresveratrol (4) through 1d and 1f, 
respectively. 5-Carboxy-oxyresveratrol (3) was 
obtained from 1d through oxidation with NaClO2 
followed by BCl3-catalyzed deprotection. 
However, our attempts to prepare 2-carboxy-
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not successful due to the decomposition of the 
oxidized product during the deprotection process. 
 
As can be seen from Table 1, oxyresveratrol (1) 
was evaluated for effects on P19-derived 
neuronal cells at various concentrations, and 
found to enhance cell viability at 1 ng/ml. When 
similarly analyzed at this concentration, the 5-
formylated and the 5-carboxylated products (2 
and 3) displayed comparable effects, but the 2-
formylated derivative (4) exhibited toxicity and 
was excluded from the following experiments. In 
a subsequent study, P19-derived cells were 
cultured in serum-deprived medium, and the cell 
viability was measured by the XTT reduction 
method (Table 2). The oxidative stress induced 
by nutrient starvation affected cell survival and as 
a result reduced the cell viability to 40 %, 
compared with the cells grown in normal 
condition. Addition of 1, 2 or 3 to the medium 
partly restored cell viability.   
 
Nutrient deprivation is known to be a stimulus for 
oxidative stress, an imbalance of free radical 
production and the antioxidant defense system. 
The production of free radicals often begins with 
the generation of superoxide anions (O2 ), 
which can then act as the precursor for the 
formation of several other reactive chemical 
species, such as H2O2, OH and NO. In this 
study, the ability of these polyoxygenated 
stilbenes (1 – 3) to enhance cell survival 
appeared to be in parallel with their O2 
scavenging activity. Compounds 2 and 3, with 
an additional electron withdrawing group such as 
CHO or COOH, showed higher superoxide 
scavenging activity and stronger cell protection 
activity than the parent compound 1. However, it 
should be kept in mind that these compounds 1 – 
3 at higher concentrations have the possibility of 
displaying toxicity, and in vivo experiments are 
thus needed to verify their neuroprotective 
potential. Recently, we have developed 
nanostructured carriers for oral delivery of 1 [19], 
which should be useful for further in vivo 




Oxyresveratrol and its derivatives, including 5-
formylated and 5-carboxylated products, 
enhance the survival of P19-derived cells in 
serum starvation condition. Their potencies are 
much higher than those of the well-known 
antioxidants, Trolox and ascorbic acid. Although 
these stilbenes are potentially of therapeutic 
value, in vivo experiments to confirm their 
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